Pharmaceutical Firms

Clears way for higher rates for Cisplatin and Carboplatin amid supply crunch

India plans a new support scheme for bulk drugs focused on R&D and capacity creation, while ruling out a broad medicine price hike despite rising input costs

Sai's management reiterated long-term guidance of 15-20 per cent revenue CAGR with 28-30 per cent steady state EBITDA margin over the next two to three years.

The Central Asian nation is offering tax breaks, infrastructure support and regulatory incentives as it seeks to become a pharmaceutical manufacturing hub for the CIS region

Cost pressures, inventory strains likely to hit margins by 3-5%

Spirulina can, indeed, prove a boon for a country like India where malnutrition, especially protein deficiency (anaemia), is rampant

Pharma major Venus Remedies Limited on Saturday said it has received marketing authorisation from the Saudi Food and Drug Authority (SFDA) for speciality oncology therapy -- Plerixafor. Plerixafor is a hematopoietic stem cell mobiliser used in combination with granulocyte-colony stimulating factor (G-CSF) to mobilise stem cells into peripheral blood for collection and autologous transplantation. It is standard-of-care in haemato-oncology, particularly for patients with multiple myeloma and non-Hodgkin lymphoma undergoing transplant, the company said in a statement. This is the first marketing authorisation the company secured for Plerixafor anywhere in the world, it added. Saransh Chaudhary, President, Global Critical Care, Venus Remedies Limited, and Venus Medicine Research Centre CEO, said, "This is our first Plerixafor approval anywhere in the world, and Saudi Arabia is the right market to launch it in". "Plerixafor sits squarely in the kind of therapy class we are building our

Parexel says India is evolving into a strategic innovation and clinical research hub as global pharmaceutical firms shift high-value functions and decision-making roles

Traditional pharmacists protest as online pharmacy firms dominate India's drug retail market, outpacing brick-and-mortar players in growth and funding

CDSCO flags one batch of a liver drug as spurious and identifies 169 drugs and formulations as not of standard quality during April surveillance

From online consults to doorstep drug deliveries, convenience is driving a new quick-fix healthcare mindset among Gen Z, which accounts for nearly 26% of India's population

Dr Reddy's CEO Erez Israeli says semaglutide, biosimilars and oncology will drive the company's next growth phase as it expands beyond traditional generics globally

Strong India and Africa growth partially offset weakness in North America as Cipla focuses on respiratory launches and regulatory filings

A risk-based system allows regulators to pay attention where it matters most, while providing industry with predictability

Cipla's March 2026 quarter revenue is expected to decline marginally to ₹6,665 crore as compared to ₹6,730 crore in the year-ago period

The Indian drugmaker is considering seeking consent from Organon bondholders to swap their holdings into Sun Pharma debt

Laurus Labs is now getting the benefit of the same as the CDMO quarterly run rate has gone up from ₹220-250 crore to ₹450-500 crore in two years, believe analysts.

Combined entity to have revenue of $12.4 billion; enters biosimilars big league

April 26 (Reuters) - India's Sun Pharmaceutical Industries ​will uy Organon & ​Co in an all-cash ‌deal, valuing the U.S. drugmaker at about $11.75 billion including ebt, the companies said on Sunday.

India's pharma and healthcare firms may post steady Q4 revenue growth, but weak US generics and rising costs are likely to keep margins under pressure